{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:39:07Z","timestamp":1792636747866,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004320","name":"Philips","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004320","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jvir.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Vascular and Interventional Radiology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jvir.2026.108910","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:20:43Z","timestamp":1781626843000},"page":"108910","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of 3-Year United States Payer Costs for Endovascular Treatment Options to Treat Femoropopliteal Artery Disease"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1666-017X","authenticated-orcid":false,"given":"Sean P.","family":"Lyden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2264-171X","authenticated-orcid":false,"given":"Henri Vanden","family":"Bavi\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Martinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margo","family":"Wheatley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trisha","family":"Tarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4676-2839","authenticated-orcid":false,"given":"William A.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvir.2026.108910_bib1","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1177\/1358863X221140151","article-title":"Demographic and regional trends of peripheral artery disease-related mortality in the United States, 2000 to 2019","volume":"28","author":"Issa","year":"2023","journal-title":"Vasc Med Lond Engl"},{"key":"10.1016\/j.jvir.2026.108910_bib2","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.atherosclerosis.2019.05.026","article-title":"Cost and inpatient burden of peripheral artery disease: findings from the National Inpatient Sample","volume":"286","author":"Kohn","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jvir.2026.108910_bib3","first-page":"E67","article-title":"The current U.S. prevalence of peripheral arterial disease","volume":"20","author":"Yost","year":"2023","journal-title":"Vasc Dis Manag"},{"key":"10.1016\/j.jvir.2026.108910_bib4","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/1477-7525-11-175","article-title":"Burden of peripheral arterial disease in Europe and the United States: a patient survey","volume":"11","author":"Marrett","year":"2013","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jvir.2026.108910_bib5","first-page":"667","article-title":"Comparative assessment of medical resource use and costs associated with patients with symptomatic peripheral artery disease in the United States","volume":"22","author":"Chase","year":"2016","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.jvir.2026.108910_bib6","doi-asserted-by":"crossref","first-page":"962","DOI":"10.2214\/AJR.19.21967","article-title":"Recent trends in endovascular and surgical treatment of peripheral arterial disease in the Medicare population","volume":"214","author":"Guez","year":"2020","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.jvir.2026.108910_bib7","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.2337\/dc20-0586","article-title":"National and state-level trends in nontraumatic lower-extremity amputation among U.S. Medicare beneficiaries with diabetes, 2000-2017","volume":"43","author":"Harding","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jvir.2026.108910_bib8","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1177\/15266028211068769","article-title":"No mortality signal with Stellarex low-dose paclitaxel DCB: ILLUMENATE pivotal 4-year outcomes","volume":"29","author":"Lyden","year":"2022","journal-title":"J Endovasc Ther"},{"key":"10.1016\/j.jvir.2026.108910_bib9","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1007\/s11886-023-01973-9","article-title":"Endovascular interventions for peripheral artery disease: a contemporary review","volume":"25","author":"Watson","year":"2023","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.jvir.2026.108910_bib10","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1016\/j.jcin.2018.08.034","article-title":"Sustainable antirestenosis effect with a low-dose drug-coated balloon: the ILLUMENATE European randomized clinical trial 2-year results","volume":"11","author":"Brodmann","year":"2018","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jvir.2026.108910_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1583\/11-3627.1","article-title":"Nitinol stent implantation vs. balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries of patients with claudication: three-year follow-up from the RESILIENT randomized trial","volume":"19","author":"Laird","year":"2012","journal-title":"J Endovasc Ther"},{"key":"10.1016\/j.jvir.2026.108910_bib12","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.118.007702","article-title":"Long-term clinical effectiveness of a drug-coated balloon for the treatment of femoropopliteal lesions","volume":"12","author":"Laird","year":"2019","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jvir.2026.108910_bib13","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1002\/bjs.9195","article-title":"Cost-effectiveness analysis of enhancements to angioplasty for infrainguinal arterial disease","volume":"100","author":"Kearns","year":"2013","journal-title":"Br J Surg"},{"key":"10.1016\/j.jvir.2026.108910_bib14","first-page":"546","article-title":"Economic analysis of endovascular interventions for femoropopliteal arterial disease: a systematic review and budget impact model for the United States and Germany","volume":"84","author":"Pietzsch","year":"2014","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.jvir.2026.108910_bib15","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-011245","article-title":"Economic analysis of endovascular drug-eluting treatments for femoropopliteal artery disease in the UK","volume":"6","author":"Katsanos","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.jvir.2026.108910_bib16","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1161\/CIRCULATIONAHA.117.028893","article-title":"Stellarex drug-coated balloon for treatment of femoropopliteal disease: twelve-month outcomes from the randomized ILLUMENATE pivotal and pharmacokinetic studies","volume":"136","author":"Krishnan","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jvir.2026.108910_bib17","first-page":"497","article-title":"Stellarex drug-coated balloon for treatment of femoropopliteal arterial disease-the ILLUMENATE Global Study: 12-month results from a prospective, multicenter, single-arm study","volume":"91","author":"Schro\u00eb","year":"2018","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.jvir.2026.108910_bib18","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1093\/eurheartj\/ehaa049","article-title":"COMPARE: prospective, randomized, non-inferiority trial of high- vs. low-dose paclitaxel drug-coated balloons for femoropopliteal interventions","volume":"41","author":"Steiner","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jvir.2026.108910_bib19","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.amjcard.2024.06.027","article-title":"Stellarex drug-coated balloon for the treatment of peripheral artery disease: five-year results from the ILLUMENATE pivotal randomized controlled trial","volume":"227","author":"Krishnan","year":"2024","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jvir.2026.108910_bib20","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1177\/1526602820948240","article-title":"Three-year results of the IN.PACT SFA Japan trial comparing drug-coated balloons with percutaneous transluminal angioplasty","volume":"27","author":"Soga","year":"2020","journal-title":"J Endovasc Ther"},{"key":"10.1016\/j.jvir.2026.108910_bib21","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.117.005891","article-title":"Treatment effect of drug-coated balloons is durable to 3 years in the femoropopliteal arteries: long-term results of the IN.PACT SFA randomized trial","volume":"11","author":"Schneider","year":"2018","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jvir.2026.108910_bib22","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jacc.2018.11.039","article-title":"Drug-eluting stent versus drug-coated balloon revascularization in patients with femoropopliteal arterialdisease","volume":"73","author":"Bausback","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jvir.2026.108910_bib23","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jacc.2022.10.016","article-title":"Comparison of drug-coated balloons vs bare-metal stents in patients with femoropopliteal arterial disease","volume":"81","author":"Shishehbor","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jvir.2026.108910_bib24","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1016\/j.jcin.2016.08.036","article-title":"Cost-effectiveness of endovascular femoropopliteal intervention using drug-coated balloons versus standard percutaneous transluminal angioplasty: results from the IN.PACT SFA II trial","volume":"9","author":"Salisbury","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"issue":"1\u2013210","key":"10.1016\/j.jvir.2026.108910_bib25","volume":"14","author":"Bradbury","year":"2010","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.jvir.2026.108910_bib26","doi-asserted-by":"crossref","first-page":"43S","DOI":"10.1016\/j.jvs.2010.01.076","article-title":"Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: health-related quality of life outcomes, resource utilization, and cost-effectiveness analysis","volume":"51","author":"Forbes","year":"2010","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.jvir.2026.108910_bib27","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jama.1995.03530020083037","article-title":"Revascularization for femoropopliteal disease. A decision and cost-effectiveness analysis","volume":"274","author":"Hunink","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.jvir.2026.108910_bib28","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1002\/bjs.9200","article-title":"Economic analysis of a randomized trial of percutaneous angioplasty, supervised exercise or combined treatment for intermittent claudication due to femoropopliteal arterial disease","volume":"100","author":"Mazari","year":"2013","journal-title":"Br J Surg"},{"key":"10.1016\/j.jvir.2026.108910_bib29","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.001233","article-title":"Cost-effectiveness of supervised exercise, stenting, and optimal medical care for claudication: results from the Claudication: Exercise Versus Endoluminal Revascularization (CLEVER) trial","volume":"3","author":"Reynolds","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jvir.2026.108910_bib30","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.jvs.2008.06.016","article-title":"Cost-effectiveness of endovascular revascularization compared to supervised hospital-based exercise training in patients with intermittent claudication: a randomized controlled trial","volume":"48","author":"Spronk","year":"2008","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.jvir.2026.108910_bib31","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1053\/ejvs.2002.1838","article-title":"Cost-effectiveness of diagnostic imaging work-up and treatment for patients with intermittent claudication in The Netherlands","volume":"25","author":"Visser","year":"2003","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.jvir.2026.108910_bib32","first-page":"133","article-title":"Cost-effectiveness analysis of orbital atherectomy plus balloon angioplasty vs balloon angioplasty alone in subjects with calcified femoropopliteal lesions","volume":"6","author":"Weinstock","year":"2014","journal-title":"Clin Outcomes Res"},{"key":"10.1016\/j.jvir.2026.108910_bib33","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1161\/CIRCULATIONAHA.115.016900","article-title":"Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the Zilver PTX randomized trial","volume":"133","author":"Dake","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jvir.2026.108910_bib34","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jvs.2013.01.050","article-title":"Three-year results of the VIBRANT trial of VIABAHN endoprosthesis versus bare nitinol stent implantation for complex superficial femoral artery occlusive disease","volume":"58","author":"Geraghty","year":"2013","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.jvir.2026.108910_bib43","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1177\/15266028211068772","article-title":"A Single-Center Study on the Outcomes of Target Limb Revascularization in Femoropopliteal Lesions Treated With Drug Coated Balloons and Bare Metal Stents","volume":"29","author":"Linehan","year":"2022","journal-title":"J Endovasc Ther"},{"key":"10.1016\/j.jvir.2026.108910_bib44","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1016\/j.jvs.2020.12.061","article-title":"Clinical outcomes of polymer-free, paclitaxel-coated stents vs stent grafts in peripheral arterial disease patients with femoropopliteal artery lesions","volume":"73","author":"Tsujimura","year":"2021","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.jvir.2026.108910_bib35","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1055\/s-0042-1759818","article-title":"Single-center study evaluating long-term major adverse outcomes with the use of paclitaxel-coated balloons in treating infrainguinal arterial disease","volume":"32","author":"Shammas","year":"2023","journal-title":"Int J Angiol"},{"key":"10.1016\/j.jvir.2026.108910_bib36","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1007\/s00270-022-03289-7","article-title":"Comparison between clinical outcomes of low- and high-dose paclitaxel drug-coated balloon in endovascular therapy for femoropopliteal lesion","volume":"46","author":"Mori","year":"2023","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.jvir.2026.108910_bib37","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/j.jcin.2022.08.004","article-title":"Low-dose vs high-dose paclitaxel-coated balloons for femoropopliteal lesions: 2-year results from the COMPARE trial","volume":"15","author":"Steiner","year":"2022","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jvir.2026.108910_bib39","first-page":"1","article-title":"ESVM guideline on peripheral arterial disease","volume":"48","author":"Frank","year":"2019","journal-title":"Vasa"},{"key":"10.1016\/j.jvir.2026.108910_bib40","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.jcin.2018.01.233","article-title":"Public health impact of the Centers for Medicare and Medicaid Services decision on pass-through add-on payments for drug-coated balloons: a call to action","volume":"11","author":"Shishehbor","year":"2018","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jvir.2026.108910_bib41","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.jvs.2017.06.112","article-title":"Cost-effectiveness analysis of drug-coated therapies in the superficial femoral artery","volume":"67","author":"Sridharan","year":"2018","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.jvir.2026.108910_bib42","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1177\/1526602820984111","article-title":"Health care utilization following inpatient femoropopliteal revascularization with drug-coated balloon angioplasty: a nationwide cohort analysis","volume":"28","author":"Gurin","year":"2021","journal-title":"J Endovasc Ther"}],"container-title":["Journal of Vascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1051044326009218?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1051044326009218?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:47:49Z","timestamp":1791323269000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1051044326009218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":43,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1051044326009218"],"URL":"https:\/\/doi.org\/10.1016\/j.jvir.2026.108910","relation":{},"ISSN":["1051-0443"],"issn-type":[{"value":"1051-0443","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of 3-Year United States Payer Costs for Endovascular Treatment Options to Treat Femoropopliteal Artery Disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Vascular and Interventional Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvir.2026.108910","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier, Inc., on behalf of SIR.","name":"copyright","label":"Copyright"}],"article-number":"108910"}}